News & Publications
Press Releases
-
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
November 11, 2022 by NanOlogy
-
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
September 20, 2022 by NanOlogy
-
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
August 1, 2022 by NanOlogy
-
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
May 3, 2022 by NanOlogy
-
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
November 9, 2021 by NanOlogy
NanOlogy in the News
-
OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
September 16, 2021 by NanOlogy
-
Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 16, 2021 by NanOlogy
-
JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
March 26, 2021 by NanOlogy
-
Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
January 9, 2020 by NanOlogy
-
Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
May 7, 2019 by NanOlogy
Presentations
- DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol
- NanOlogy General Presentation (June 2022)
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
Publications
- Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
- Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery
- Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
Upcoming NanOlogy Events
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
